Literature DB >> 16124035

High-throughput screening of inhibitory potential of nine cytochrome P450 enzymes in vitro using liquid chromatography/tandem mass spectrometry.

Min-Jung Kim1, Hyojin Kim, In-June Cha, Jang-Su Park, Ji-Hong Shon, Kwang-Hyeon Liu, Jae-Gook Shin.   

Abstract

The early detection of potential drug-drug interactions is an important issue of drug discovery that has led to the development of high-throughput screening (HTS) methods for potential drug interactions. We developed a HTS method for potential interactions of inhibitory drugs for nine human P450 enzymes using cocktail incubation and tandem mass spectrometry in vitro. This new method involves incubation of two cocktail doses and single cassette analysis. The two cocktail doses in vitro were developed to minimize solvent effects and mutual drug interactions among substrates: cocktail A was composed of phenacetin for CYP1A2, coumarin for CYP2A6, paclitaxel for CYP2C8, S-mephenytoin for CYP2C19, dextromethorphan for CYP2D6, and midazolam for CYP3A4; and cocktail B was composed of three substrates including bupropion for CYP2B6, tolbutamide for CYP2C9, and chlorzoxazone for CYP2E1. In the incubation study of these cocktails, the reaction mixtures were pooled and simultaneously analyzed using liquid chromatography/tandem mass spectrometry employing a fast gradient. The method was validated by comparing the inhibition data obtained from the incubation of each individual probe substrate alone with data from the new method. The IC50 value of each inhibitor in the cocktail agreed well with that of the individual probe drug as well as with values previously reported in the literature. As a HTS method for potential interactions of the inhibition of these nine P450 enzymes, this new method will be useful in the drug discovery process and for the mechanistic understanding of drug interactions. Copyright (c) 2005 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16124035     DOI: 10.1002/rcm.2110

Source DB:  PubMed          Journal:  Rapid Commun Mass Spectrom        ISSN: 0951-4198            Impact factor:   2.419


  24 in total

1.  High-Throughput Cytochrome P450 Cocktail Inhibition Assay for Assessing Drug-Drug and Drug-Botanical Interactions.

Authors:  Guannan Li; Ke Huang; Dejan Nikolic; Richard B van Breemen
Journal:  Drug Metab Dispos       Date:  2015-08-18       Impact factor: 3.922

2.  CYP2J2 and CYP2C19 are the major enzymes responsible for metabolism of albendazole and fenbendazole in human liver microsomes and recombinant P450 assay systems.

Authors:  Zhexue Wu; Doohyun Lee; Jeongmin Joo; Jung-Hoon Shin; Wonku Kang; Sangtaek Oh; Do Yup Lee; Su-Jun Lee; Sung Su Yea; Hye Suk Lee; Taeho Lee; Kwang-Hyeon Liu
Journal:  Antimicrob Agents Chemother       Date:  2013-08-19       Impact factor: 5.191

3.  Effects of nicotine on cytochrome P450 2A6 and 2E1 activities.

Authors:  Janne Hukkanen; Peyton Jacob Iii; Margaret Peng; Delia Dempsey; Neal L Benowitz
Journal:  Br J Clin Pharmacol       Date:  2010-02       Impact factor: 4.335

4.  Identification of key licorice constituents which interact with cytochrome P450: evaluation by LC/MS/MS cocktail assay and metabolic profiling.

Authors:  Xue Qiao; Shuai Ji; Si-Wang Yu; Xiong-Hao Lin; Hong-Wei Jin; Yao-Kai Duan; Liang-Ren Zhang; De-An Guo; Min Ye
Journal:  AAPS J       Date:  2013-11-20       Impact factor: 4.009

5.  Preparation and Evaluation of Potent Pentafluorosulfanyl-Substituted Anti-Tuberculosis Compounds.

Authors:  Garrett C Moraski; Ryan Bristol; Natalie Seeger; Helena I Boshoff; Patricia Siu-Yee Tsang; Marvin J Miller
Journal:  ChemMedChem       Date:  2017-06-27       Impact factor: 3.466

6.  Coupling IR-MALDESI with Drift Tube Ion Mobility-Mass Spectrometry for High-Throughput Screening and Imaging Applications.

Authors:  Måns Ekelöf; James Dodds; Sitora Khodjaniyazova; Kenneth P Garrard; Erin S Baker; David C Muddiman
Journal:  J Am Soc Mass Spectrom       Date:  2020-02-11       Impact factor: 3.109

7.  The influence of the CYP2C19*10 allele on clopidogrel activation and CYP2C19*2 genotyping.

Authors:  Taimour Y Langaee; Hao-Jie Zhu; Xinwen Wang; Nihal El Rouby; John S Markowitz; Joyce A Goldstein; Julie A Johnson
Journal:  Pharmacogenet Genomics       Date:  2014-08       Impact factor: 2.089

8.  The use of immobilized cytochrome P4502C9 in PMMA-based plug flow bioreactors for the production of drug metabolites.

Authors:  Lance A Wollenberg; Jarod L Kabulski; Matthew J Powell; Jifeng Chen; Darcy R Flora; Timothy S Tracy; Peter M Gannett
Journal:  Appl Biochem Biotechnol       Date:  2013-10-30       Impact factor: 2.926

9.  Effect of a New Prokinetic Agent DA-9701 Formulated with Corydalis Tuber and Pharbitidis Semen on Cytochrome P450 and UDP-Glucuronosyltransferase Enzyme Activities in Human Liver Microsomes.

Authors:  Hye Young Ji; Kwang Hyeon Liu; Ji Hyeon Jeong; Dae-Young Lee; Hyun Joo Shim; Miwon Son; Hye Suk Lee
Journal:  Evid Based Complement Alternat Med       Date:  2012-04-02       Impact factor: 2.629

10.  Lead Optimization in Discovery Drug Metabolism and Pharmacokinetics/Case study: The Hepatitis C Virus (HCV) Protease Inhibitor SCH 503034.

Authors:  K-C Cheng; Walter A Korfmacher; Ronald E White; F George Njoroge
Journal:  Perspect Medicin Chem       Date:  2007-06-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.